Tag: Parkinson’s

Two studies show lack of benefit in primary or secondary end points with cinpanemab or prasinezumab versus placebo

Among patients with Parkinson disease, SNCA or GBA mutations associated with shorter survival compared with no mutations

During median follow-up of 21 years, risk reduced for Parkinson disease, secondary parkinsonism after MI

Higher flavonoid intake after diagnosis of Parkinson disease linked to reduced risk for all-cause mortality

Regular physical activity levels linked to slower deterioration of postural and gait stability, activities of daily living, processing speed

No measurable difference in patient-rated quality of life seen for dopamine agonists versus dopamine reuptake inhibitors as adjuvant therapy

In young veterans with traumatic brain injury, performance on some cognitive tests similar to that of older adults with early Parkinson disease

Levodopa preferred as initial dopaminergic therapy for motor symptoms in patients with early Parkinson disease

Increases seen across all age groups, both sexes, various racial/ethnic groups, different urban/rural classifications

Highest increased risk for developing Parkinson disease seen among those with knee or hip osteoarthritis